CJA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Submit a scholarly reply
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hall, R.
Right arrow Articles by Murdoch, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hall, R.
Right arrow Articles by Murdoch, J.

Canadian Journal of Anesthesia, Vol 37, 762-777, Copyright © 1990 by Canadian Anesthesiologists' Society

ARTICLES

Brain protection: physiological and pharmacological considerations. Part II: The pharmacology of brain protection

R Hall and J Murdoch
Department of Anaesthesiology, Dalhousie University, Halifax, Nova Scotia, Canada.

Neuroprotective agents may exert their effect by reducing cerebral oxygen demand (CMRO2), increasing cerebral oxygen delivery, or by altering ongoing pathological processes. Barbiturates provide neuroprotection by reducing the CMRO2 necessary for synaptic transmission while leaving the component necessary for cellular metabolism intact. Isoflurane may exert a neuroprotective effect by a similar mechanism but its efficacy is likely less than that of barbiturates due to adverse effects on cerebral blood flow. Lidocaine reduces CMRO2 by affecting both cellular metabolic processes and synaptic transmission and thus resembles hypothermia in its mechanism of action. Benzodiazepines reduce CMRO2 by reducing synaptic transmission and their use as neuroprotectants produces less haemodynamic compromise than barbiturates. The mechanism of protection by calcium entry blocking agents appears to be due to improved blood flow as opposed to altering abnormal Ca++ fluxes. In contrast, agents such as ketamine and MK-801 may prevent abnormal Ca++ fluxes through their competitive interaction with N-methyl-D-aspartate receptors. Phenytoin prevents K(+)-mediated ischaemic events from progressing. Agents worthy of further investigation include corticosteroids, free radical scavengers, prostaglandin inhibitors and iron chelators.


This article has been cited by other articles:


Home page
 Ann. Thorac. Surg.Home page
G. Amir, C. Ramamoorthy, R. K. Riemer, V. M. Reddy, and F. L. Hanley
Neonatal Brain Protection and Deep Hypothermic Circulatory Arrest: Pathophysiology of Ischemic Neuronal Injury and Protective Strategies
Ann. Thorac. Surg., November 1, 2005; 80(5): 1955 - 1964.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurophysiol.Home page
D. A. Nita, S. Vanhatalo, F.-D. Lafortune, J. Voipio, K. Kaila, and F. Amzica
Nonneuronal Origin of CO2-Related DC EEG Shifts: An In Vivo Study in the Cat
J Neurophysiol, August 1, 2004; 92(2): 1011 - 1022.
[Abstract] [Full Text] [PDF]

Home page
 Epidemiol RevHome page
B. A. in 't Veld, L. J. Launer, M. M. B. Breteler, A. Hofman, and B. H. Ch. Stricker
Pharmacologic Agents Associated with a Preventive Effect on Alzheimer's Disease: A Review of the Epidemiologic Evidence
Epidemiol. Rev., December 1, 2002; 24(2): 248 - 268.
[Full Text] [PDF]

Home page
 StrokeHome page
L. Regli, R. E. Anderson, and F. B. Meyer
Effects of Intermittent Reperfusion on Brain pHi, rCBF, and NADH During Rabbit Focal Cerebral Ischemia
Stroke, August 1, 1995; 26(8): 1444 - 1452.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1990 by the Canadian Anesthesiologists' Society.